Clinical momentum Actym is advancing ACTM-838 in a Phase 1a/b with key clinical updates expected in 3Q 2025, signaling near-term visibility for potential collaboration or investment discussions and a window for partnership conversations aligned with clinical readouts.

Strategic platform STACT is a modular delivery platform designed to target tumor-resident myeloid cells and locally amplify therapeutic payloads, presenting multiple collaboration avenues beyond ACTM-838 and enabling partnerships with companies seeking novel immuno-oncology delivery modalities.

Immuno-oncology need By aiming to convert cold tumors to hot while minimizing systemic exposure, Actym addresses a core limitation of current IO therapies, creating sales opportunities with pharma companies focused on overcoming immune-suppressive tumor microenvironments.

Leadership updates Recent hires of a Chief Scientific Officer and a Senior VP of Clinical Development strengthen leadership and execution capability, which can accelerate discussions with potential CROs, academic collaborators, and strategic investors seeking a robust operating team.

Financial runway With a Series A funding round completed and ongoing funding of about $60M, Actym demonstrates financial backing and growth potential that can support co-development deals, milestone-driven partnerships, and external validation for potential buyers or venture partners.